4//SEC Filing
Minkow Emily 4
Accession 0001209191-20-018117
CIK 0001714798other
Filed
Mar 10, 8:00 PM ET
Accepted
Mar 11, 4:47 PM ET
Size
7.2 KB
Accession
0001209191-20-018117
Insider Transaction Report
Form 4
Minkow Emily
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2019-12-24$0.18/sh+13,000$2,340→ 13,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-12-24−13,000→ 149,000 totalExercise: $0.18Exp: 2027-10-24→ Common Stock (13,000 underlying)
Footnotes (1)
- [F1]25% of the total number of shares underlying the option vested and became exercisable on November 6, 2018 and an additional 1/48th of the total number of shares underlying the option vests and becomes exercisable on the first day of each of the thirty-six (36) consecutive months thereafter subject, in all cases, to the Reporting Person providing continuous service with the Issuer on each such date.
Documents
Issuer
Prevail Therapeutics Inc.
CIK 0001714798
Entity typeother
Related Parties
1- filerCIK 0001778491
Filing Metadata
- Form type
- 4
- Filed
- Mar 10, 8:00 PM ET
- Accepted
- Mar 11, 4:47 PM ET
- Size
- 7.2 KB